Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.90
-5.0%		$2.71
$1.90
▼
$12.30
$2.03M1.16955,559 shs34,014 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.53
+15.1%		$0.42
$0.23
▼
$2.75
$8.91M1393,326 shs2.66 million shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.44
+4.2%		$0.59
$0.16
▼
$15.75
$8.26M21.24 million shs341,015 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shs50 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-5.00%-12.84%-13.24%-41.54%-83.93%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+15.07%+33.42%+11.09%+95.26%-78.58%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+4.25%-9.20%-42.22%-80.61%-96.52%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%-89.90%-89.90%-79.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.90
-5.0%		$2.71
$1.90
▼
$12.30
$2.03M1.16955,559 shs34,014 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.53
+15.1%		$0.42
$0.23
▼
$2.75
$8.91M1393,326 shs2.66 million shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.44
+4.2%		$0.59
$0.16
▼
$15.75
$8.26M21.24 million shs341,015 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shs50 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-5.00%-12.84%-13.24%-41.54%-83.93%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+15.07%+33.42%+11.09%+95.26%-78.58%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+4.25%-9.20%-42.22%-80.61%-96.52%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%-89.90%-89.90%-79.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
2.67
Moderate Buy$44.002,215.79% Upside
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1.00
SellN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.33
Hold$3.00578.73% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CANF, MBRX, ENSC, and OBSV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/29/2026
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/28/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$3.00
7/17/2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$405K5.02N/AN/A$1.76 per share1.08
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/A$0.63 per shareN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$4.69 per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$14.80N/AN/AN/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.18M-$2.76N/AN/AN/A-280.53%-2,550.30%-320.49%11/13/2026 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$33.56M-$7.13N/AN/AN/AN/A-143.51%-24.53%11/12/2026 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A

Latest CANF, MBRX, ENSC, and OBSV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.20-$0.20N/A-$0.20$1.20 million$1.16 million
8/13/2026Q2 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$1.55-$1.40+$0.15-$1.40N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
0.70
0.70
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
0.94
0.94
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
2.80%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
18.04%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
51.07 millionN/ANot Optionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1019.46 million18.91 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1719.48 million15.96 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable

Recent News About These Companies

ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
August 31, 2024  |  pharmaphorum.comP
ObsEva SA OBSN
November 11, 2023  |  morningstar.comM
ObsEva SA OBSEF
November 11, 2023  |  morningstar.comM
ObsEva (NASDAQ: OBSV)
June 18, 2023  |  fool.comhttps://www.fool.com/quote/nasdaq/obsv/
Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver
May 10, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance
May 2, 2023  |  news.google.comN
ObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq
May 2, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire
May 2, 2023  |  news.google.comN
Gameto Appoints Teri Loxam as Chief Financial Officer - citybiz
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Marketscreener.com
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Yahoo Finance
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Benzinga
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - EIN News
April 28, 2023  |  news.google.comN
Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire
April 28, 2023  |  news.google.comN
Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal
April 26, 2023  |  news.google.comN
Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR
April 23, 2023  |  news.google.comN
ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com
April 21, 2023  |  news.google.comN
ObsEva Announces Change of Central Securities Depositary - Yahoo Finance
April 20, 2023  |  news.google.comN
ObsEva Announces Change of Central Securities Depositary - GlobeNewswire
April 20, 2023  |  news.google.comN
Tackling Reproductive Health and Fertility Care - Pharmaceutical Executive
April 13, 2023  |  news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$1.90 -0.10 (-5.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.89 -0.01 (-0.68%)
As of 10/9/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$0.53 +0.07 (+15.07%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$0.52 -0.01 (-1.90%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.44 +0.02 (+4.25%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$0.45 +0.01 (+2.26%)
As of 10/9/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas